| P50 | author | Bruno Giordani | Q97525044 |
| P2093 | author name string | Robert A Koeppe | |
| | Michael R Kilbourn | |
| | Sid Gilman | |
| | Roger L Albin | |
| | James F Burke | |
| | Kirk A Frey | |
| P2860 | cites work | Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia | Q60042388 |
| | Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. | Q67234444 |
| | Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system | Q70793970 |
| | Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis | Q71922028 |
| | A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET | Q72334971 |
| | Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias | Q73086543 |
| | On the Regulation of the Blood-supply of the Brain | Q24554227 |
| | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| | Focal cortical presentations of Alzheimer's disease | Q28250737 |
| | Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 |
| | Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | Q29397661 |
| | Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium | Q29614409 |
| | Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria | Q29614410 |
| | Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory | Q29614724 |
| | Mild cognitive impairment as a diagnostic entity | Q29619568 |
| | Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia | Q30486197 |
| | Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. | Q30920239 |
| | Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. | Q30984127 |
| | Brain work and brain imaging | Q31044322 |
| | Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. | Q33864626 |
| | Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology | Q34244675 |
| | 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. | Q34423994 |
| | Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. | Q34727992 |
| | PET studies in dementia | Q35147026 |
| | Positron emission tomography scans obtained for the evaluation of cognitive dysfunction | Q35446894 |
| | Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia | Q35450021 |
| | Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand | Q35468295 |
| | Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease | Q35758632 |
| | White matter lesions impair frontal lobe function regardless of their location | Q35844738 |
| | FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease | Q36912674 |
| | Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias | Q36990181 |
| | Imaging amyloid deposition in Lewy body diseases | Q37087766 |
| | Positron emission tomography imaging in dementia. | Q37150643 |
| | Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease | Q37219754 |
| | The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias | Q37239001 |
| | Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease | Q38394208 |
| | Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies | Q38841875 |
| | Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. | Q39171874 |
| | Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. | Q40415499 |
| | In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. | Q40467939 |
| | Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment | Q40716303 |
| | Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation | Q43738764 |
| | Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome | Q43788870 |
| | Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia | Q44009309 |
| | Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias | Q44060087 |
| | Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. | Q44249033 |
| | Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? | Q44411562 |
| | Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study | Q44452244 |
| | Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment | Q44571913 |
| | Brain metabolic differences between sporadic and familial Alzheimer's disease. | Q44634161 |
| | Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease | Q44918550 |
| | 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. | Q45254010 |
| | Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. | Q46043966 |
| | Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. | Q46111835 |
| | What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? | Q46349482 |
| | Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. | Q46920843 |
| | 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis | Q46981595 |
| | Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution | Q48147364 |
| | Imaging beta-amyloid burden in aging and dementia. | Q48168226 |
| | 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration | Q48210315 |
| | Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study | Q48240563 |
| | Cerebral glucose metabolism in patients with frontotemporal dementia. | Q48342474 |
| | Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia | Q48493223 |
| | Cortical abnormalities in Alzheimer's disease | Q48597181 |
| | Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography | Q48624000 |
| | Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease | Q48671019 |
| | Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. | Q48747176 |
| | FDG PET imaging in patients with pathologically verified dementia. | Q52023258 |
| | Impairment of neocortical metabolism predicts progression in Alzheimer's disease. | Q52137678 |
| | Anatomic standardization: linear scaling and nonlinear warping of functional brain images. | Q52371563 |
| | Pathological and positron emission tomographic correlations in Alzheimer's disease. | Q53189657 |
| | In vivo amyloid imaging with PET in frontotemporal dementia. | Q53289124 |
| | Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. | Q53340013 |
| P433 | issue | 4 | |
| P921 | main subject | mild cognitive impairment | Q1472703 |
| | cognitive dysfunction | Q57859955 |
| P304 | page(s) | 440-446 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Archives of Neurology | Q15766672 |
| P1476 | title | Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment | |
| P478 | volume | 67 | |